GSK plc (NYSE:GSK) Shares Sold by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC lessened its position in GSK plc (NYSE:GSK) by 29.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,048 shares of the pharmaceutical company’s stock after selling 7,706 shares during the period. Kestra Private Wealth Services LLC’s holdings in GSK were worth $669,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC raised its holdings in shares of GSK by 7.7% during the third quarter. FMR LLC now owns 18,099,513 shares of the pharmaceutical company’s stock valued at $656,107,000 after buying an additional 1,291,161 shares during the last quarter. Primecap Management Co. CA raised its stake in GSK by 2.4% during the 3rd quarter. Primecap Management Co. CA now owns 12,058,770 shares of the pharmaceutical company’s stock valued at $437,130,000 after acquiring an additional 287,000 shares in the last quarter. Royal Bank of Canada boosted its position in GSK by 5.1% during the 3rd quarter. Royal Bank of Canada now owns 8,079,897 shares of the pharmaceutical company’s stock worth $292,896,000 after acquiring an additional 389,871 shares during the period. Morgan Stanley increased its holdings in shares of GSK by 2.1% during the third quarter. Morgan Stanley now owns 7,551,555 shares of the pharmaceutical company’s stock valued at $273,744,000 after purchasing an additional 156,480 shares during the period. Finally, Provident Trust Co. increased its holdings in shares of GSK by 53.6% during the fourth quarter. Provident Trust Co. now owns 3,716,830 shares of the pharmaceutical company’s stock valued at $137,746,000 after purchasing an additional 1,297,385 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on GSK shares. Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Morgan Stanley initiated coverage on shares of GSK in a research note on Tuesday, January 23rd. They set an “equal weight” rating on the stock. Finally, Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, GSK has an average rating of “Moderate Buy”.

GSK Price Performance

Shares of GSK stock opened at $43.50 on Monday. GSK plc has a 52 week low of $33.33 and a 52 week high of $43.84. The company has a current ratio of 0.87, a quick ratio of 0.62 and a debt-to-equity ratio of 1.15. The stock has a market cap of $90.15 billion, a PE ratio of 15.76, a price-to-earnings-growth ratio of 1.49 and a beta of 0.65. The company’s 50-day moving average price is $41.87 and its two-hundred day moving average price is $39.18.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be issued a $0.3762 dividend. This is an increase from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 dividend on an annualized basis and a dividend yield of 3.46%. The ex-dividend date is Thursday, May 16th. GSK’s payout ratio is presently 57.61%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.